Last updated: September 8, 2026
Vasopressin is a mature injectable peptide used primarily in hospital critical-care settings for vasodilatory shock, septic shock and post-cardiotomy vasoplegia. The market is shifting from a branded-product model led by Endo Pharmaceuticals’ Vasostrict to a multi-source generic market. Revenue growth is constrained by generic price erosion, hospital purchasing pressure and intermittent supply disruption, while demand remains supported by intensive-care utilization and vasopressin’s role as an adjunct to catecholamine therapy.
Vasopressin is not a biosimilar market. FDA-approved competitors use the abbreviated new drug application pathway because vasopressin is a chemically defined active pharmaceutical ingredient rather than a biologic.
What is vasopressin used for, and how large is the market?
Vasopressin injection is used to increase vascular tone and blood pressure in patients with vasodilatory shock. The principal commercial formulation is an intravenous injection, commonly supplied at 20 units/mL.
| Market attribute |
Assessment |
| Active ingredient |
Vasopressin, synthetic peptide |
| Primary setting |
Hospital intensive-care and operating-room use |
| Principal indication |
Vasodilatory shock, including septic shock |
| Dosage form |
Sterile intravenous injection |
| Primary U.S. product |
Vasostrict |
| Competitive pathway |
ANDA generics |
| Reimbursement |
Hospital purchasing, inpatient reimbursement and group purchasing organization contracts |
| Retail exposure |
Limited |
| Biosimilar exposure |
None |
| Main commercial risk |
Generic price erosion and supply interruptions |
The addressable market is concentrated in hospitals rather than retail pharmacies. Demand is tied to admissions requiring vasopressor support, surgical volume, cardiac surgery, emergency medicine and critical-care protocols. Vasopressin is usually purchased as part of a broader hospital injectable portfolio that includes norepinephrine, epinephrine, phenylephrine and injectable corticosteroids.
Public market-size estimates vary materially because analysts use different definitions. Some count only branded and generic vasopressin injection sales. Others include global hospital purchases, compounded supply, related vasopressin analogues or the broader vasopressor market. U.S. branded revenue is therefore a more reliable measure of the commercial trajectory than a single global market-size estimate.
How has the vasopressin market evolved financially?
The market has moved through four stages:
- An older low-price injectable market with limited commercial differentiation.
- The launch and expansion of Vasostrict as a branded, FDA-approved formulation.
- Patent and regulatory challenges from generic manufacturers.
- Multi-source competition with lower prices and reduced branded pricing power.
Vasostrict became the principal commercial product in the U.S. hospital market after FDA approval of Endo’s product in 2014. The product generated substantial branded revenue despite the age of the active ingredient because the approved formulation, manufacturing controls, hospital supply reliability and regulatory labeling differentiated it from older compounded or less consistently supplied products.
The financial trajectory has since become more difficult. FDA-approved generic entry reduced the ability to sustain premium pricing. Vasopressin remains clinically relevant, but its mature therapeutic profile limits volume expansion. Revenue is now driven mainly by hospital utilization, contract retention, supply availability and net price.
| Financial driver |
Directional effect |
| ICU and surgical utilization |
Supports volume |
| Generic entry |
Reduces net price |
| Hospital group purchasing |
Reduces gross-to-net realization |
| Supply shortages |
Can increase short-term demand for available suppliers |
| New clinical indications |
Limited expansion potential |
| Brand differentiation |
Narrower after generic approval |
| Manufacturing scale |
Important for margin and contract competitiveness |
Endo’s public filings have historically included Vasostrict within product-level or portfolio disclosures, but the company’s reporting structure and restructuring have changed over time. Vasopressin is not generally reported as a standalone revenue category by every manufacturer. Generic suppliers also typically disclose broader injectable or hospital-product results rather than vasopressin-specific sales.
What patents protect Vasostrict and other vasopressin products?
The active ingredient is old and does not have meaningful composition-of-matter exclusivity. The relevant intellectual-property risk has centered on formulation, concentration, manufacturing and regulatory approval rather than ownership of vasopressin itself.
The best-known U.S. patent associated with Vasostrict is U.S. Patent No. 8,178,489, directed to vasopressin formulations. Public patent databases and FDA Orange Book records have associated the patent with the Vasostrict product and an expiration date in 2026, subject to statutory adjustments and any applicable regulatory extensions.[1][2]
| IP category |
Commercial relevance |
| Vasopressin molecule |
Minimal current exclusivity value because the molecule is old |
| Formulation patents |
Historically important to Vasostrict’s branded protection |
| Concentration and stability claims |
Can support Orange Book listing or litigation positions |
| Manufacturing know-how |
Relevant to sterility, stability and scale |
| Method-of-use claims |
Potentially relevant but generally weaker than formulation protection |
| Trade secrets |
May protect process parameters but do not block an approved ANDA by themselves |
Patent protection for vasopressin is materially weaker than the estate for a new chemical entity. A generic manufacturer can often design around narrow formulation claims if it can demonstrate pharmaceutical equivalence, bioequivalence and adequate stability.
When does vasopressin lose exclusivity?
Vasopressin’s practical exclusivity has already declined because the molecule is off-patent and FDA-approved generic products have entered the U.S. market. The remaining branded patent timeline is less important than the timing and commercial scale of generic approvals.
The key dates are:
| Event |
Date or status |
| Vasostrict FDA approval |
2014 |
| Orphan-drug exclusivity |
Historically associated with the approved indication; seven-year period ended before or around the period of generic competition |
| Formulation patent associated with Vasostrict |
U.S. Patent No. 8,178,489; commonly reported expiration in 2026 |
| Generic FDA approvals |
Began entering the market in the early 2020s |
| Current market structure |
Branded product plus approved generic injectable competition |
Orphan exclusivity is indication-specific and does not create a broad monopoly over all vasopressin products. It also does not prevent approval of a product that is shown to be clinically different or approved for a different use under applicable FDA rules.
The 2026 patent date may remain relevant to settlement economics, authorized-generic strategy and litigation risk. It does not necessarily restore the pre-generic pricing structure.
Which companies are challenging or competing with Vasostrict?
Generic competition has come primarily from established injectable manufacturers rather than emerging biotechnology companies. Publicly identified or market-relevant competitors have included Hikma Pharmaceuticals and other suppliers pursuing or commercializing generic vasopressin injection.
The competitive field is shaped by FDA approval status, manufacturing capacity and hospital contracting rather than consumer brand recognition.
| Company type |
Competitive position |
| Endo and affiliated entities |
Originator and Vasostrict rights holder |
| Hikma Pharmaceuticals |
Established generic injectable competitor |
| Other ANDA applicants |
Potential price and supply competitors |
| Contract manufacturers |
Possible source of finished-dose supply |
| Compounding pharmacies |
Supplemental or shortage-related supply, subject to applicable rules |
| Hospital systems |
Large purchasers with negotiating power |
The most important competitor is often the supplier that can maintain uninterrupted delivery. Hospitals may tolerate limited price differences when a product is clinically essential and supply reliability is uncertain.
What is the Orange Book status of vasopressin?
The Orange Book is relevant primarily to FDA-approved branded products and associated patents. Vasostrict’s listing history has been important because patent certifications from ANDA applicants can trigger Hatch-Waxman litigation.
A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. The certification can enable the brand company to file an infringement action and obtain a statutory stay of FDA approval, subject to the timing and procedural requirements of the Hatch-Waxman Act.[3]
For vasopressin, the commercial impact of Orange Book litigation has been reduced by the market’s age and by the availability of generic entry after the relevant exclusivity barriers weakened. Patent disputes can still affect launch timing, damages exposure and settlement terms.
What patent litigation and settlement risks affect vasopressin?
Vasopressin litigation risk has centered on whether generic formulations infringe listed formulation patents. Typical disputes involve:
- The composition and concentration of the injectable solution.
- Stability characteristics.
- Excipients and pH control.
- Manufacturing or storage conditions.
- The scope of claims in the listed formulation patent.
- Whether the ANDA product is a direct infringement risk.
A settlement can permit a generic launch before patent expiry, either on a specified date or subject to commercial conditions. Such agreements can reduce litigation expense but may preserve branded revenue for a defined period. The economic value of a settlement depends on the number of approved or pending ANDAs, the strength of the patent claims and the generic entrant’s ability to secure hospital contracts.
There is no biosimilar litigation pathway for vasopressin. Regulatory disputes proceed through the generic-drug framework, not the Public Health Service Act biosimilar framework.
What formulation patents protect vasopressin injection?
Formulation protection is the principal historical barrier. A product such as Vasostrict can obtain commercial value from a stable, sterile, ready-to-use formulation even when the active molecule itself is old.
Relevant formulation attributes include:
- Unit concentration.
- Peptide stability over the labeled shelf life.
- Sterility assurance.
- Container closure integrity.
- Compatibility with intravenous administration.
- Preservation and storage requirements.
- Manufacturing reproducibility at commercial scale.
Formulation patents have limited blocking power when claims are narrow. A generic company can challenge validity, argue non-infringement or develop a formulation that meets FDA requirements without practicing every claimed limitation.
Manufacturing know-how remains commercially relevant after patent expiry. Sterile injectable manufacturing has higher technical and regulatory barriers than tablet production. FDA inspection findings, particulate contamination, fill-finish capacity, container shortages and quality-system failures can remove a supplier from the market even after its legal barriers have fallen.
What method-of-use patents cover vasopressin?
Method-of-use protection is narrower than formulation protection. Vasopressin is used in multiple clinical settings, including septic shock and perioperative vasoplegia. A method patent may cover a dosing regimen, patient population or combination with another vasopressor.
The practical value of a method-of-use patent is limited where:
- The indication is already established in clinical practice.
- The generic label omits a patented use.
- Physicians prescribe the product for an unclaimed use.
- The patented method represents only a small portion of total demand.
- Hospitals rely on clinical protocols rather than brand-directed prescribing.
A skinny-label strategy can reduce direct infringement exposure for a generic while leaving the product commercially useful for non-patented indications.
How strong is the vasopressin patent estate?
The estate is moderate to weak relative to a recently launched innovative drug.
| Strength factor |
Assessment |
| Composition-of-matter protection |
Very weak or absent |
| Formulation protection |
Historically meaningful |
| Patent life |
Limited, with key protection reported through 2026 |
| Design-around risk |
Moderate |
| Regulatory complexity |
Meaningful because the product is sterile injectable |
| Litigation leverage |
Declining after generic entry |
| Manufacturing barrier |
More durable than molecule-based IP |
| Revenue protection after 2026 |
Low without supply or contracting advantages |
The strongest residual barriers are operational rather than legal. A supplier with reliable sterile manufacturing, adequate inventory and hospital contracts can retain share after patent expiry. A patent holder without supply advantages is more exposed to price erosion.
How does vasopressin compare with competing vasopressors?
Vasopressin is usually an adjunct rather than the sole first-line vasopressor for septic shock. Norepinephrine remains the standard initial agent in major clinical guidelines, while vasopressin is added when blood pressure remains inadequate or norepinephrine requirements rise.[4]
| Product |
Typical role |
Commercial distinction |
| Norepinephrine |
First-line vasopressor in septic shock |
High-volume generic market |
| Vasopressin |
Adjunct for vasodilatory shock |
Lower volume, concentrated critical-care demand |
| Epinephrine |
Rescue or additional vasopressor support |
Broad emergency and critical-care use |
| Phenylephrine |
Selected hypotension settings |
Strong perioperative and ICU demand |
| Angiotensin II |
Rescue therapy in selected patients |
Newer, higher-price specialty product |
Vasopressin’s value is tied to mechanism and clinical positioning. It can reduce reliance on catecholamines in selected patients, but it does not have the broad first-line utilization of norepinephrine.
What generic launch scenarios exist for vasopressin?
Three scenarios define the post-brand market:
Early multi-source erosion
Several approved suppliers compete simultaneously. Hospital buyers use bidding and group purchasing contracts to reduce price. Branded share declines quickly, and the originator retains business mainly through supply reliability or contracting.
Constrained generic competition
Only one or two manufacturers maintain consistent supply. Prices decline less sharply, particularly during shortages. The originator can preserve some volume through dependable distribution.
Shortage-driven volatility
A manufacturing interruption removes one or more suppliers. Available products gain temporary pricing power, but hospitals and regulators increase pressure for supply restoration. Revenue can rise briefly without representing durable market expansion.
The most likely long-term scenario is a low-growth, multi-source injectable market with intermittent volatility. Revenue increases are more likely to result from price or supply events than from sustained clinical adoption.
What is the FDA regulatory status of vasopressin?
Vasopressin injection is FDA-approved and regulated as a prescription sterile injectable. Vasostrict was approved under an NDA, while generic versions proceed through ANDAs demonstrating pharmaceutical equivalence and bioequivalence or other applicable approval requirements.[1]
FDA regulatory risk includes:
- Sterility and particulate contamination.
- Manufacturing-site compliance.
- Stability data.
- Labeling differences.
- Product availability during shortages.
- Container and closure performance.
- Post-approval quality events.
Because hospitals depend on reliable sterile injectables, an FDA warning letter or manufacturing suspension can have an immediate commercial effect.
What licensing deals affect vasopressin?
Vasopressin has had fewer high-value licensing transactions than newer specialty pharmaceuticals. The commercial structure has generally involved originator ownership, generic development and manufacturing or distribution arrangements rather than major discovery-stage licensing.
Potential transaction value is concentrated in:
- Rights to Vasostrict or successor branded assets.
- Authorized-generic arrangements.
- Generic injectable portfolios.
- Contract manufacturing capacity.
- Hospital distribution and group purchasing access.
- Rights in specific geographic territories.
The asset’s mature status limits the value of broad exclusivity deals. Buyers are more likely to value supply reliability, regulatory history and contract access than long-term innovation potential.
What is the geographic coverage of vasopressin IP and competition?
U.S. commercial economics are distinct from other regions. Patent scope, regulatory approval, hospital procurement and supply-chain structure vary by country.
| Region |
Market characteristics |
| United States |
Orange Book litigation, ANDA competition and GPO purchasing |
| European Union |
National tendering and decentralized reimbursement |
| Japan |
Hospital and reimbursement controls with local approval requirements |
| China |
Local procurement pressure and increasing price competition |
| Emerging markets |
Greater dependence on local manufacturers and public tenders |
A U.S. formulation patent does not automatically block sales elsewhere. International protection depends on national filings, patent term, regulatory approval and local enforcement.
What revenue exposure does vasopressin create for manufacturers?
For Endo, Vasostrict historically represented a material branded-product asset. The exposure has declined as generic competition expanded and the company underwent restructuring. For generic manufacturers, vasopressin is usually a portfolio product rather than a standalone growth platform.
Financial exposure is highest when a manufacturer:
- Relies heavily on a single sterile injectable facility.
- Has limited hospital-product diversification.
- Holds a large share of contracted volume.
- Cannot pass through manufacturing-cost inflation.
- Faces a competitor with lower cost or greater capacity.
The market is attractive as a portfolio complement because demand is recurring and clinical use is established. It is less attractive as a standalone innovation investment because volume growth is limited and legal exclusivity is weak.
Key Takeaways
- Vasopressin is a mature hospital injectable market led historically by Vasostrict.
- The active ingredient has little current exclusivity value; formulation and manufacturing protection have carried most of the commercial weight.
- U.S. generic competition began in the early 2020s and has reduced branded pricing power.
- U.S. Patent No. 8,178,489 is the principal publicly associated Vasostrict formulation patent, with expiration commonly reported in 2026.
- Vasopressin has no biosimilar pathway; competitors use the ANDA generic-drug pathway.
- Financial performance depends on hospital utilization, supply reliability, contracts and generic intensity.
- Manufacturing quality and uninterrupted sterile supply are more durable advantages than molecule-level IP.
- Long-term market growth is likely to be limited, with revenue volatility driven by shortages and contract changes.
- Vasopressin compares favorably with other mature injectables as a recurring hospital product, but it lacks the growth profile and patent strength of innovative specialty drugs.
FAQs About Vasopressin Market and Patent Risk
Is vasopressin still commercially protected by a composition patent?
No. The active ingredient is an old synthetic peptide. Current protection has focused on formulation, manufacturing and use-related claims.
Can a generic vasopressin product launch before the 2026 patent expiration?
Yes. Launch timing can result from patent invalidity or non-infringement findings, settlement agreements, authorized-generic arrangements or other legal outcomes.
Is Vasostrict a biologic drug?
No. Vasostrict contains synthetic vasopressin and is regulated as a drug product, not as a biologic requiring a biosimilar application.
Why can vasopressin prices rise after generic approval?
Sterile injectable shortages, manufacturing failures, limited supplier capacity and hospital inventory constraints can temporarily outweigh normal generic price competition.
Does vasopressin have significant clinical growth potential?
Growth is limited. Demand can increase with ICU and surgical utilization, but vasopressin is generally an adjunctive vasopressor and competes with established generic alternatives.
References
- U.S. Food and Drug Administration. (2014). Vasostrict: Prescribing information and approval history. Drugs@FDA.
- U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,178,489, Vasopressin formulations.
- U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations. Orange Book.
- Society of Critical Care Medicine. (2021). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Critical Care Medicine, 49(11), e1063-e1143.
